Roche said on it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the third and last phase of testing on humans.

Treatment with salanersen slowed neurodegeneration and improved motor function in children with SMA in a Phase 1 trial, interim results show.

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed in two earlier studies that missed their main goals.

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that ...

The development program for AD109 includes a second Phase 3 trial testing the drug in OSA patients for one year. Apnimed expects preliminary data from this study in the third quarter of 2025.

Roche moves antibiotic against superbug into Phase 3 of testing. By Reuters. May 26, 2025 3:44 PM UTC Updated May 26, 2025 A sign at a diagnostics site for Swiss pharmaceutical ...